Frontline Stock (NYSE:FRO), Trade Ideas

Frontline

Frontline Plc is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ALPN

ALTI

ANAB

ELVN

FVRR

GYRE

JANX

NEXN

NRIX

RLYB

STEP

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.

Shares of  Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

Price Target

Analyst Ratings

ALIT

AVGO

CROX

FIVE

ORIC

TSHA

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday

Earnings

Equities

Frontline Plc reported Q4 revenue of $415M, beating consensus of $270.06M. Net income, EPS, and cash flow all decreased compared to last year.

Frontline Outperforms Q4 Revenue Estimates; Strategic Asset Sales And Refinancing Bolster Financial Position

Frontline Plc

JFrog Ltd

Frontier - United States Dollar

FRONTEO INC by FRONTEO, Inc.

FRONTIER NATL CORP by Frontier National Corp.

FRONTAGE HLDGS CORP by Frontage Hldgs Corp.

Frontage Holdings Corp

FRONTAGE HLDG CP UNSP/ADR by Frontage Hldgs Corp.

Frontdoor Inc

FRONTERA ENERGY CORP ORD by Frontera Energy Corp

Frontera Energy Corp

FRONTERA GROUP INC by Frontera Group Inc.

Frontera Group Inc

FRONTERA INVESTMENT INC by Frontera Investment, Inc.

Frontera Investment Inc

Frontier Communications Parent, Inc. - Common Stock

Frontier Communications Parent Inc

FRONTIER DEVS PLC ORD by Frontier Devs PLC

Frontier Developments PLC

FRONTIER DIGITAL VENTURES by Frontier Digital Ventures Ltd

Frontier Digital Ventures Ltd

FRONTIER ENERGY CORP by Frontier Energy Corp.

Frontier Energy Corporation

FRONTIER ENERGY LIMITED by Frontier Energy Limited

Frontier Energy Ltd

Frontier Group Holdings, Inc. - Common Stock

Frontier Group Holdings Inc

Frontier Investment Corp Warrants (29/06/2026)

Frontier Investment Corp

Frontier Investment Corp Units (1 Ord Share Class A & 1/3 War)

Frontier Investment Corp Ordinary Shares - Class A

Frontier Lithium Inc

FRONTIER RE INVST by Frontier Real Estate Invest,

Frontier Real Estate Investment Corp

FRONTIER SERVICES GRP LTD by Frontier Services Group Ltd

Frontier Services Group Ltd

HOSKEN PASSENGER LOGISTIC by HOSKEN PASSENGER LOGISTICS & RAIL LTD.

Frontier Transport Holdings Ltd

FRONTLINE GOLD CORP by Frontline Gold Corp.

Frontline Gold Corp

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elvn#NASDAQ">ELVN</a>) rose sharply during Thursday&rsquo;s session.
Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in <a href="https://www.benzinga.com/general/biotech/24/04/38199756/enliven-therapeutics-announces-proof-of-concept-data-from-phase-1-clinical-trial-of-elvn-001-in-c">chronic myeloid leukemia</a>.
Enliven Therapeutics shares surged 26% to $24.97 on Thursday.
Here are some other big stocks recording losses in today&rsquo;s session.
<ul>
<li>Rallybio Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlyb#NASDAQ">RLYB</a>) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson &amp; Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) jumped 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.</li>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) shares jumped 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) rose 14.6% to $15.91.</li>
<li>AnaptysBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anab#NASDAQ">ANAB</a>) rose 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.</li>
<li>Fiverr International Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fvrr#NYSE">FVRR</a>) gained 10.5% to $21.25 after the company&#39;s board authorized a $100 million share repurchase program.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) shares jumped 10.2% to $34.18.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) climbed 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.</li>
<li>AlTi Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alti#NASDAQ">ALTI</a>) gained 9.3% to $5.06.</li>
<li>Nexxen International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexn#NASDAQ">NEXN</a>) rose 7.3% to $5.62.</li>
<li>StepStone Group LP (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/step#NASDAQ">STEP</a>) gained 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.</li>
<li>Frontline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fro#NYSE">FRO</a>) rose 5.9% to $24.47.</li>
<li>IAMGOLD Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iag#NYSE">IAG</a>) gained 3.6% to $3.74.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/04/38200324/dell-designer-brands-and-2-other-stocks-insiders-are-selling"> Dell, Designer Brands And 2 Other Stocks Insiders Are Selling</a>

Ratings for Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.66, along with a high estimate of $30.00 and a low estimate of $22.00. Observing a 6.61% increase, the current average has risen from the previous average price target of $23.13. 
<img src="https://www.benzinga.com/files/images/story/2024/1711047630_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Frontline by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Samuel Bland</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.30</td>
<td>$23.00</td>
</tr>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Bland</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$24.40</td>
</tr>
<tr>
<td>Amit Mehrotra</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Frontline. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Frontline compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Frontline's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Frontline's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Frontline analyst ratings.</a>
<h2>All You Need to Know About Frontline</h2>
Frontline Plc is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
<h3>Understanding the Numbers: Frontline's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Frontline faced challenges, resulting in a decline of approximately -1.33% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 28.57%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.76%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Frontline's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.32%, the company showcases efficient use of assets and strong financial health.
Debt Management: Frontline's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.01.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Frontline Stock: Analyst Perspectives (5 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Rosenblatt boosted the price target for Micron Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mu#NASDAQ">MU</a>) from $140 to $225. Rosenblatt analyst Hans Mosesmann maintained a Buy rating. Micron shares gained 2.4% to close at $96.25 on Wednesday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased the price target for Alight, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alit#NYSE">ALIT</a>) from $12 to $13. Needham analyst Kyle Peterson maintained a Buy rating. Alight shares jumped 14% to close at $10.08 on Wednesday. <a href="https://www.benzinga.com/quote/ALIT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised ORIC Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oric#NASDAQ">ORIC</a>) price target from $15 to $21. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. ORIC Pharmaceuticals shares rose 0.3% to close at $14.36 on Wednesday. <a href="https://www.benzinga.com/quote/ORIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen raised the price target for Broadcom Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avgo#NASDAQ">AVGO</a>) from $1,400 to $1,500. TD Cowen analyst Matthew Ramsay upgraded the stock from Market Perform to Outperform. Broadcom shares gained 3.5% to close at $1,276.00 on Wednesday. <a href="https://www.benzinga.com/quote/AVGO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised Guess?, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ges#NYSE">GES</a>) price target from $23 to $30. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Guess shares rose 3.1% to close at $25.95 on Wednesday. <a href="https://www.benzinga.com/quote/GES/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc boosted the price target for Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) from $130 to $149. Keybanc analyst Chandana Madaka maintained an Overweight rating. Crocs shares gained 6.3% to close at $139.99 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut Five Below, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/five#NASDAQ">FIVE</a>) price target from $230 to $220. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Five Below shares gained 1.1% to close at $208.97 on Wednesday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital boosted Taysha Gene Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsha#NASDAQ">TSHA</a>) price target from $5 to $7. Chardan Capital analyst Geulah Livshits maintained a Buy rating. Taysha Gene Therapies shares gained 31.6% to close at $2.96 on Wednesday. <a href="https://www.benzinga.com/quote/TSHA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised Frontline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fro#NYSE">FRO</a>) price target from $22 to $30. Jefferies analyst Omar Nokta upgraded the stock from Hold to Buy. Frontline shares fell 2.5% to close at $22.64 on Wednesday. <a href="https://www.benzinga.com/quote/FRO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised ZTO Express (Cayman) Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zto#NYSE">ZTO</a>) price target from $22 to $29. B of A Securities analyst Fan Tso upgraded the stock from Neutral to Buy. ZTO Express shares rose 4.4% to close at $22.61 on Wednesday. <a href="https://www.benzinga.com/quote/ZTO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/03/37863674/micron-accenture-and-3-stocks-to-watch-heading-into-thursday"> Micron, Accenture And 3 Stocks To Watch Heading Into Thursday </a>

WIIM

Frontline shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $22 to $30.

Jefferies analyst Omar Nokta upgrades Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) from Hold to Buy and raises the price target from $22 to $30.

Upgrades

Jefferies Upgrades Frontline to Buy, Raises Price Target to $30

In the last three months, 4 analysts have published ratings on Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Frontline and provided 12-month price targets. The average target is $23.32, accompanied by a high estimate of $26.00 and a low estimate of $22.00. This current average has decreased by 1.6% from the previous average price target of $23.70. 
<img src="https://www.benzinga.com/files/images/story/2024/1709312439_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Frontline among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel Bland</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.30</td>
<td>$23.00</td>
</tr>
<tr>
<td>Omar Nokta</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Samuel Bland</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$24.40</td>
</tr>
<tr>
<td>Amit Mehrotra</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Frontline. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Frontline compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Frontline's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Frontline analyst ratings.</a>
<h2>All You Need to Know About Frontline</h2>
Frontline Plc is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
<h3>Financial Insights: Frontline</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Frontline faced challenges, resulting in a decline of approximately -1.33% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: Frontline's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 28.57% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Frontline's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.76%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Frontline's ROA excels beyond industry benchmarks, reaching 2.32%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.01, Frontline adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Frontline

JP Morgan analyst Samuel Bland maintains Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) with a Neutral and lowers the price target from $23 to $22.3.

JP Morgan Maintains Neutral on Frontline, Lowers Price Target to $22.3

Frontline Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) reported a fourth-quarter fiscal 2023&nbsp;<a target="_blank" href="https://www.frontlineplc.cy/fro-fourth-quarter-and-full-year-2023-results/" rel="noreferrer noopener">revenue&nbsp;</a>decline of 21.8% year-over-year to $415 million, beating the consensus of $270.06 million.
The company&#8217;s reported spot TCEs for VLCCs, Suezmax tankers, and LR2/Aframax tankers were 42,300 (vs. 42,500 in Q3), 45,700 (vs. 37,600 in Q3) and 42,900 (vs. 33,900 in Q3) per day.&nbsp;
The company expects the spot TCEs for the first quarter of 2024 to be lower than the TCEs currently contracted due to the impact of ballast days at the end of the fourth quarter.&nbsp;&nbsp;
Net operating income for the quarter declined to $138.05 million from $245.407 million a year ago. Adjusted EPS was $0.46 versus $0.96 a year ago, in line with the consensus.
FRO&#8217;s operating cash flow was $100.49 million compared to $222.16 million a year ago. The company held cash and cash equivalents of $308.32 million as of December 31, 2023.
In the quarter, Frontline Ltd. sold its five oldest VLCCs (from 2009 and 2010) and an old Suezmax tanker (from 2010) for $335 million in total. The company is also refinancing eight Suezmax and 16 LR2 tankers, which are expected to bring in about $408 million in net cash.
These transactions, totaling roughly $646 million in proceeds, will enable Frontline to repay the Hemen shareholder loan and clear the $275 million credit facility used for an Acquisition.
&#8220;The continuous disruption in the Red Sea has caused West / East trading lanes to widen, which we believe benefits the larger vessel classes, offering economies of scale as oil and products move around the Cape of Good Hope,&#8221; commented Lars H. Barstad, Chief Executive Officer of Frontline Management AS.
As of December 31, 2023, the company&#8217;s fleet consisted of 76 vessels owned by the company (33 VLCCs, 25 Suezmax tankers, 18 LR2/Aframax tankers), with an aggregate capacity of approximately 15.9 million DWT.&nbsp;&nbsp;
Dividend:&nbsp;The company declared a dividend of $0.37 per share for the quarter, payable on or about March 27, 2024. The record date for the dividend will be March 15, 2024.
Price Action: FRO shares are trading lower by 1.01% at $22.516 on the last check Thursday.

Jefferies analyst Omar Nokta reiterates Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) with a Hold and maintains $22 price target.

Reiteration

Jefferies Reiterates Hold on Frontline, Maintains $22 Price Target

ABUS

ACIC

ACIW

ADSK

AINC

AKLI

AMRN

AMWD

ANIP

ARGX

ARLO

AVPT

BBWI

BIRK

BLFS

BRFH

CAPR

CCOI

CDRO

CELH

CERT

CMPS

CMRX

COMM

CPSI

CRAI

CRDF

CRON

CUBE

CVEO

DAVA

DELL

DHIL

DMTK

DOLE

DOUG

ESAB

ESTC

EVLV

EVRG

EVRI

EXLS

FDUS

FIHL

FREY

FSCO

GDEN

GDRX

GECC

GLNG

GOLF

GOVX

GRBK

HAYW

HYFM

IHRT

INSW

INUV

ITRN

JAKK

KPTI

LSEA

LSTA

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

MNTX

MPLN

NBBK

Earnings Scheduled For February 29, 2024

Frontline Q4 Adj EPS $0.46, Inline, Sales $415.00M Beat $270.06M Estimate

JP Morgan analyst Samuel Bland maintains Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) with a Neutral and lowers the price target from $24 to $23.

JP Morgan Maintains Neutral on Frontline, Lowers Price Target to $23

<h3>Understanding Value Stocks</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>Benzinga Insights has compiled a list of value stocks in the energy sector that may be worth watching:</h2>
<ol>
<li>GeoPark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) - P/E: 3.7</li>
<li>Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) - P/E: 8.32</li>
<li>Callon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPE#NYSE">CPE</a>) - P/E: 3.24</li>
<li>DHT Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>) - P/E: 9.26</li>
<li>Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) - P/E: 6.2</li>
</ol>
GeoPark's earnings per share for Q3 sits at $0.44, whereas in Q2, they were at 0.59. The company's most recent dividend yield sits at 5.43%, which has increased by 0.45% from 4.98% last quarter. 
Antero Resources has reported Q3 earnings per share at $0.08, which has increased by 128.57% compared to Q2, which was -0.28. Most recently, Callon Petroleum reported earnings per share at $1.82, whereas in Q2 earnings per share sat at $1.99. DHT Holdings saw a decrease in earnings per share from 0.35 in Q2 to $0.19 now. Its most recent dividend yield is at 6.75%, which has decreased by 7.51% from 14.26% in the previous quarter.
Frontline saw a decrease in earnings per share from 0.94 in Q2 to $0.36 now. The company's most recent dividend yield sits at 15.82%, which has increased by 14.5% from 1.32% last quarter. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

GPRK

A Look Into Energy Sector Value Stocks

Deutsche Bank analyst Amit Mehrotra upgrades Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) from Hold to Buy and announces $26 price target.

Deutsche Bank Upgrades Frontline to Buy, Announces $26 Price Target

Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) has observed the following analyst ratings within the last quarter: 
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the last 3 months, 5 analysts have offered 12-month price targets for Frontline. The company has an average price target of $19.86 with a high of $22.00 and a low of $18.20. 
Below is a summary of how these 5 analysts rated Frontline over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1701374418_0.png" alt="price target chart" />
This current average has increased by 11.26% from the previous average price target of $17.85. 
<a href="https://www.benzinga.com/quote/FRO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Frontline analyst ratings.</a>
<h1>Analyst Ratings: What Are They?</h1>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About Frontline

Shares of Titan Machinery Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/titn#NASDAQ">TITN</a>) moved lower during Thursday&rsquo;s trading following weak quarterly results.
Titan Machinery posted quarterly earnings of $1.32 per share, missing market estimates of $1.53 per share. The company&rsquo;s quarterly sales came in at $694.12 million versus estimates of $727.20 million.
Titan Machinery shares declined 8.1% to $23.41 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Minim Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares jumped 700% to $7.36 after gaining over 13% on Wednesday.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agri#NASDAQ">AGRI</a>) gained 174% to $2.47.</li>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) surged 116% to $0.90 after the company announced it received FDA IND clearance for the Phase 2 clinical trial of dusquetide in the treatment of aphthous ulcers of Beh&ccedil;et&#39;s disease.</li>
<li>ImmunoGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imgn#NASDAQ">IMGN</a>) shares jumped 80% to $28.89 after AbbVie announced it will acquire the company in a transaction valued at $31.26 per share in cash.</li>
<li>Smart for Life, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smfl#NASDAQ">SMFL</a>) gained 46% to $2.2221.</li>
<li>Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) shares climbed 45% to $5.00.</li>
<li>REX American Resources Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rex#NYSE">REX</a>) gained 30.7% to $48.22 following strong third-quarter results.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) rose 24.2% to $5.03 after surging 22% on Wednesday. Clearmind Medicine recently announced results from its weight loss and metabolic disorder program.</li>
<li>Ucommune International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uk#NASDAQ">UK</a>) gained 21.8% to $6.58.</li>
<li>Ampio Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ampe#NASDAQ">AMPE</a>) shares surged 21% to $2.3750 after gaining over 3% on Wednesday.</li>
<li>Reborn Coffee, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rebn#NASDAQ">REBN</a>) gained 19.5% to $0.6216. Reborn Coffee announced conversion of $1 million of outstanding debt into common equity.</li>
<li>Zuora, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zuo#NASDAQ">ZUO</a>) gained 19.5% to $9.98 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>SpringWorks Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swtx#NASDAQ">SWTX</a>) climbed 18.3% to $31.75.</li>
<li>Jeffs&#39; Brands Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfbr#NASDAQ">JFBR</a>) gained 17% to $3.65.</li>
<li>The InterGroup Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intg#NASDAQ">INTG</a>) rose 13.7% to $25.50.</li>
<li>Victoria&#39;s Secret &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vsco#NYSE">VSCO</a>) climbed 13.6% to $26.80 following third-quarter results.</li>
<li>VinFast Auto Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vfs#NASDAQ">VFS</a>) gained 11.7% to $8.44 after gaining around 8% on Wednesday.</li>
<li>Farfetch Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ftch#NYSE">FTCH</a>) rose 11.2% to $1.0842.</li>
<li>Salesforce, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crm#NYSE">CRM</a>) shares gained 8.4% to $249.69 after the company reported third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>Oatly Group AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otly#NASDAQ">OTLY</a>) gained 7.5% to $1.0750.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) climbed 7.1% to $187.76 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>Nutanix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntnx#NASDAQ">NTNX</a>) rose 5% to $43.61 after the company reported better-than-expected first-quarter financial results and raised FY24 revenue guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vivos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvos#NASDAQ">VVOS</a>) shares fell 40.7% to $24.30. Vivos Therapeutics shares jumped around 832% on Wednesday after the company announced it received FDA 510(k) clearance for treating severe obstructive sleep apnea in adults using the Vivos&#39; removable CARE oral appliances.</li>
<li>RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) fell 35.6% to $1.8499 after gaining 26% on Wednesday. On Monday, Redhill Biopharma announced that the FDA had granted five years&#39; market exclusivity for its drug, Talicia, on top of three years&#39; exclusivity granted for the approval of Talicia.</li>
<li>POET Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/poet#NASDAQ">POET</a>) fell 31.4% to $0.7603 after the company reported pricing of $1.4 million underwritten public offering of common shares and warrants.</li>
<li>Elevai Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elab#NASDAQ">ELAB</a>) fell 28% to $2.54.</li>
<li>XORTX Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xrtx#NASDAQ">XRTX</a>) fell 26.8% to $2.2226.</li>
<li>PROOF Acquisition Corp I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/paci#NASDAQ">PACI</a>) declined 25% to $24.00.</li>
<li>Lizhi Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lizi#NASDAQ">LIZI</a>) fell 21.5% to $2.9750 following third-quarter results.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) declined 14.6% to $22.45.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crev#NASDAQ">CREV</a>) fell 14.3% to $33.00.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) fell 14.2% to $32.54 after the company reported worse-than-expected third-quarter revenue results and issued FY24 revenue guidance below estimates.</li>
<li>Nvni Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvni#NASDAQ">NVNI</a>) shares fell 12.2% to $2.03 after gaining over 5% on Wednesday.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) fell 11.8% to $25.55 following FY23 results.</li>
<li>Weibo Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wb#NASDAQ">WB</a>) declined 11.5% to $10.02 after the company announced a proposed offering of $300 million convertible senior notes and a proposed offering of ADSs in connection with the Delta Placement of Borrowed ADSs.</li>
<li>BRP Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dooo#NASDAQ">DOOO</a>) fell 10.6% to $62.48 following third-quarter results.</li>
<li>Movado Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mov#NYSE">MOV</a>) fell 9.4% to $26.25 following weak sales.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) fell 9.4% to $2.40 after dipping 14% on Wednesday.</li>
<li>Frontline plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fro#NYSE">FRO</a>) shares fell 6.7% to $19.77 following downbeat third-quarter earnings.</li>
<li>Cracker Barrel Old Country Store, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cbrl#NASDAQ">CBRL</a>) declined 6.5% to $70.21 following weak results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/11/36016689/how-to-make-500-a-month-with-pfizer-stock"> How To Make $500 A Month With Pfizer Stock</a>

ADTX

AGRI

AMPE

ARWR

CBRL

CMND

CREV

DOOO

ELAB

FTCH

IMGN

INTG

JFBR

LIZI

MINM

NTNX

NVNI

OTLY

PACI

POET

PSTG

RDHL

REBN

SMFL

SNGX

SNOW

SWTX

Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session